title: Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?
abstract: We herein report a case of a thalassemic-patient who was on deferasirox chelation therapy and admitted to the emergency department because of fever, diffuse abdominal pain and altered mental status. Despite the appropriate treatment he died two days later due to cardiac arrest. As we failed to recognize any etiology and the patients' relatives denied a post mortem examination due to religious reasons, we cannot provide any additional data. However, we are wondering whether this incident might be related to deferasirox.
authors.affiliation: Second Medical Department, Hippokration University Hospital, Aristotle University Thessaloniki, Greece. efivlachaki@yahoo.gr.
authors.forename: Efthimia
authors.initials: E
authors.lastname: Vlachaki
authors.forename: K
authors.initials: K
authors.lastname: Chatzinikolaou
authors.forename: E
authors.initials: E
authors.lastname: Bekiari
authors.forename: F
authors.initials: F
authors.lastname: Klonizakis
authors.forename: A
authors.initials: A
authors.lastname: Tsapas
mesh_terms: D000328:Adult; D001565:Benzoates / Q000009:adverse effects*; D015913:Chelation Therapy / Q000009:adverse effects*; D000077588:Deferasirox; D017809:Fatal Outcome; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects*; D008297:Male; D009102:Multiple Organ Failure / Q000139:chemically induced*; D012307:Risk Factors; D014230:Triazoles / Q000009:adverse effects*; D017086:beta-Thalassemia / Q000188:drug therapy*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox